The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT).
Sharlene Gill
No relevant relationships to disclose
Yoo-Joung Ko
No relevant relationships to disclose
M. Christine Cripps
No relevant relationships to disclose
Annie Beaudoin
No relevant relationships to disclose
Sukhbinder K. Dhesy-Thind
No relevant relationships to disclose
Muhammad Zulfiqar
Consultant or Advisory Role - Sanofi Canada
Pawel Zalewski
Honoraria - Sanofi Canada
Thuan Do
No relevant relationships to disclose
Pablo Oscar Cano
No relevant relationships to disclose
Wendy Lam
No relevant relationships to disclose
Scot D. Dowden
Consultant or Advisory Role - Sanofi Canada
Honoraria - Sanofi Canada
Helene Grassin
Employment or Leadership Position - Sanofi Canada
John Stewart
Employment or Leadership Position - Sanofi Canada
Stock Ownership - Sanofi Canada
Malcolm J. Moore
Research Funding - Sanofi Canada